Effetti clinici e biologici della terapia epigenetica nelle sindromi mielodisplastiche a basso rischio
Background: Nucleoside 5-Azacitidine (5-Aza) in high risk MDS patients (pts) at a dose of 75mg/mq/day subcutaneously for 7 days, every 28 days, induces high hematologic response rates (hematologic improvement (HI) 50-60%, complete remission (CR) 10-30%) and prolongation of survival (at 2 years 50,8...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Doctoral Thesis |
| Language: | it |
| Published: |
Alma Mater Studiorum - Università di Bologna
2010
|
| Subjects: | |
| Online Access: | http://amsdottorato.unibo.it/2419/ |